Establishment Labs Holdings Inc. (NASDAQ:ESTA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have been given an average rating of “Moderate Buy” by the five research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $52.40.

A number of research analysts have recently issued reports on the stock. Stephens reiterated an “overweight” rating and set a $52.00 price objective on shares of Establishment Labs in a report on Thursday, March 6th. Needham & Company LLC restated a “buy” rating and set a $48.00 price target on shares of Establishment Labs in a report on Friday, June 13th. Wall Street Zen upgraded shares of Establishment Labs from a “sell” rating to a “hold” rating in a report on Saturday, June 14th. Finally, BTIG Research assumed coverage on shares of Establishment Labs in a report on Friday, May 16th. They set a “buy” rating and a $62.00 price target on the stock.

Establishment Labs Trading Up 0.2%

ESTA opened at $40.93 on Friday. Establishment Labs has a 1-year low of $26.56 and a 1-year high of $52.41. The company has a current ratio of 3.36, a quick ratio of 2.05 and a debt-to-equity ratio of 5.72. The company has a market cap of $1.18 billion, a P/E ratio of -13.20 and a beta of 0.74. The company has a fifty day moving average price of $35.37 and a two-hundred day moving average price of $36.92.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.13. The firm had revenue of $41.38 million during the quarter, compared to analysts’ expectations of $41.15 million. Establishment Labs had a negative net margin of 52.34% and a negative return on equity of 196.25%. The business’s revenue was up 11.3% on a year-over-year basis. During the same period last year, the company earned ($0.58) earnings per share. Analysts predict that Establishment Labs will post -2.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quarry LP bought a new stake in shares of Establishment Labs in the fourth quarter valued at approximately $27,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Establishment Labs in the first quarter valued at approximately $81,000. KLP Kapitalforvaltning AS bought a new stake in shares of Establishment Labs in the fourth quarter valued at approximately $161,000. Elevation Point Wealth Partners LLC bought a new stake in shares of Establishment Labs in the first quarter valued at approximately $207,000. Finally, Patriot Financial Group Insurance Agency LLC bought a new stake in Establishment Labs during the 1st quarter worth approximately $234,000. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.